Syndax Pharmaceuticals, Inc. (Syndax)

Oncology Corporate Profile

HQ Location

460 Totten Pond Road, Suite 650
Waltham, MA 2451

Company Description

Syndax is developing entinostat for the treatment of patients with therapy-resistant cancers. Entinostat is designed to prolong the effectiveness of current cancer treatments through an epigenetic mechanism and has been designated a Breakthrough Therapy by the FDA when used in combination with exemestane in HR+ advanced breast cancer. The company holds worldwide rights to entinostat, an oral, selective HDAC inhibitor that is being evaluated in combination with exemestane in E2112, a pivotal phase III clinical study for the treatment of HR+ advanced breast cancer.

Website: http://www.syndax.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
entinostat (+ Aromasin®)HDAC inhibitorBreast CancerIII
entinostat (+ Keytruda®)HDAC inhibitorMelanomaII
entinostat (+ Keytruda®)HDAC inhibitorNon Small Cell Lung Cancer (NSCLC)II
entinostat (+ avelumab)HDAC inhibitorOvarian cancerII
entinostat (+ Tecentriq®)HDAC inhibitorTriple negative Breast cancerII

View additional information on product candidates here »

Source: http://www.syndax.com/

Recent News Headlines

Syndax Expands Pipeline With Exclusive Worldwide License Agreement for UCB’s Colony Stimulating Factor 1 Receptor (CSF-1R) Antibody Program

7/6/2016 05:19 pm

(PharmiWeb) July 6, 2016 - IND-ready immuno-oncology agent has best in class potential.

ASCO Urges Congress, CMS to Ensure Access to Cancer Care for Medicare Beneficiaries

3/21/2016 07:01 am

(ASCO) Mar 18, 2016 - The American Society of Clinical Oncology (ASCO) asked Congress to work with the provider community to address serious concerns that patient-centered, evidence-based cancer care for Medicare beneficiaries may be impeded as implementation of the Medicare Access and CHIP Reauthorization Act (MACRA) moves forward.

Merck, Pfizer and Syndax Announce Collaboration to Evaluate Combination of Avelumab and Entinostat in Ovarian Cancer

1/4/2016 05:01 pm

(StreetInsider) Jan 4, 2016 – Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Pharmaceuticals, Inc. announced today that they have entered into a collaboration agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Syndax’s entinostat, an investigational oral small molecule that targets immune regulatory cells (myeloid-derived suppressor cells and regulatory T-cells), in patients with heavily pre-treated, recurrent ovarian cancer.

Syndax Reports First Patients Dosed In Phase 1b/2 Trial Of Entinostat, KEYTRUDA

9/28/2015 07:02 pm

(NASDAQ/RTTNews.com) Sept 28, 2015 - Syndax Pharmaceuticals Inc. and Merck & Co. Inc. announced the dosing of the first patients in the Phase 1b/2 clinical trial of Syndax's entinostat in combination with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients with non-small cell lung cancer (NSCLC) or melanoma.

Syndax Enters Clinical Trial Collaboration in Cancer Immunotherapy Combining Entinostat and Atezolizumab

8/26/2015 04:52 pm

(Yahoo! Finance) Aug 26, 2015 - Phase 1b/2 trial with Genentech will assess the safety and efficacy of combining these investigational therapies for the treatment of triple-negative breast cancer.

AstraZeneca R&D Executive Morrison to Lead Cancer Firm Syndax

6/16/2015 05:07 pm

(TD Waterhouse/Reuters) June 15, 2015 - AstraZeneca's outgoing chief medical officer and head of global late-stage drug development Briggs Morrison, whose departure from the British drugmaker was announced last week, is to head U.S. cancer firm Syndax Pharmaceuticals.

Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma

3/31/2015 04:49 pm

(Merck) Mar 31, 2015 - Syndax Pharmaceuticals, Inc., and Merck announced today that they have entered into a clinical trial collaboration to evaluate the safety and efficacy of combining Syndax’s entinostat, an investigational epigenetic therapy, with Merck’s KEYTRUDA® (pembrolizumab), the first anti-PD-1 therapy approved in the United States.

Journey Forward and ERS Advance Survivorship Care Planning Through Data Integration

3/18/2015 12:01 pm

(MarketWatch) Mar 17, 2015 - Journey Forward, a leader in survivorship care planning, and Electronic Registry Services (ERS), a leading provider of cancer registry software, today announced a successful implementation that enhances the use of patient data in after-care plans.

Felicitex Therapeutics, Selvita to Battle Quiescent Cancers

11/11/2014 06:01 am

(Genetic Engineering & Biotechnology News) Nov 7, 2014 - Polish drug discovery company Selvita is partnering with cancer-focused firm Felicitex Therapeutics to develop personalized therapeutics for quiescent cancers including pancreatic, colon, ovarian, lung, and hematopoietic tumors.

Insurers Hesitant To Cover Many Proton Beam Therapy Treatments

9/23/2014 05:04 am

(Kaiser Health News) Sept 23, 2014 - Some insurers and disease experts say that, until there’s better evidence that proton therapy is more effective at treating various cancers than traditional types of less expensive radiation, coverage shouldn’t be routine.

First Patient Enrolled in ECOG-ACRIN Phase III Trial of Syndax’s Entinostat

6/30/2014 05:41 pm

(PRWeb) June 30, 2014 - The ECOG-ACRIN Cancer Research Group and Syndax Pharmaceuticals Inc. announced today enrollment of the first patient in E2112, a randomized phase III clinical trial of Syndax’s histone deacetylase (HDAC) inhibitor, entinostat, for the treatment of patients with advanced breast cancer.

First Patient Enrolled in ECOG-ACRIN Phase III Trial of Syndax’s Entinostat

6/30/2014 07:04 am

(PRWeb) June 30, 2014 - The ECOG-ACRIN Cancer Research Group and Syndax Pharmaceuticals Inc. announced today enrollment of the first patient in E2112, a randomized phase III clinical trial of Syndax’s histone deacetylase (HDAC) inhibitor, entinostat, for the treatment of patients with advanced breast cancer.

Hunterdon Regional Cancer Center to Offer Immuno-therapy Trial for Lung Cancer

6/10/2014 06:03 am

(NJ.com/Hunterdon County Democrat) June 10, 2014 - Hunterdon Regional Cancer Center was selected as the only cancer facility in New Jersey to offer a clinical study on a new lung cancer investigational drug call Nivolumab, which is made by Bristol-Myers Squibb.

ECOG-ACRIN Opens Phase III Trial of Syndax's Entinostat in Advanced Breast Cancer

3/20/2014 04:29 pm

(PRWeb) Mar 20, 2014 – The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and Syndax Pharmaceuticals, Inc., announced today that patient recruitment has begun for E2112, a randomized phase III clinical trial of Syndax’s entinostat in treatment of patients with advanced breast cancer.

ECOG-ACRIN Opens Phase III Trial of Syndax's Entinostat in Advanced Breast Cancer

3/20/2014 11:02 am

(PRWeb) Mar 20, 2014 – The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and Syndax Pharmaceuticals, Inc., announced today that patient recruitment has begun for E2112, a randomized phase III clinical trial of Syndax’s entinostat in treatment of patients with advanced breast cancer.

Who Really Cost Mrs. Blackwood Her Cancer Medicine?

2/25/2014 11:05 am

(Los Angeles Times) Feb 24, 2014 - The story is a lot more complicated than the version laid out in Stephen J. Blackwood's passionate op-ed in the Wall Street Journal.

Syndax Announces NCI and FDA Reach Agreement on a Special Protocol Assessment (SPA) for the Phase 3 Trial of Entinostat in Patients with Advanced ER+ Breast Cancer

2/13/2014 06:01 pm

(TheStreet) Feb 13, 2014 - Syndax Pharmaceuticals, Inc., today announced that the Division of Cancer Treatment and Diagnosis (DCTD) of the National Cancer Institute (NCI) has reached a special protocol assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the planned pivotal Phase 3 trial of entinostat in patients with advanced breast cancer.

Syndax Announces NCI and FDA Reach Agreement on a Special Protocol Assessment (SPA) for the Phase 3 Trial of Entinostat in Patients with Advanced ER+ Breast Cancer

2/13/2014 12:00 pm

(TheStreet) Feb 13, 2014 - Syndax Pharmaceuticals, Inc., today announced that the Division of Cancer Treatment and Diagnosis (DCTD) of the National Cancer Institute (NCI) has reached a special protocol assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the planned pivotal Phase 3 trial of entinostat in patients with advanced breast cancer.

Leading Breast Cancer Expert, George W. Sledge, Jr., M.D., Joins Syndax as an Independent Director

2/3/2014 06:25 pm

(Syndax Pharmaceuticals) Feb 3, 2014 - Syndax Pharmaceuticals, Inc., today announced the appointment of distinguished breast cancer specialist, George W. Sledge, Jr., M.D., to its board of directors as an independent director.

Leading Breast Cancer Expert, George W. Sledge, Jr., M.D., Joins Syndax as an Independent Director

2/3/2014 12:02 pm

(Syndax Pharmaceuticals) Feb 3, 2014 - Syndax Pharmaceuticals, Inc., today announced the appointment of distinguished breast cancer specialist, George W. Sledge, Jr., M.D., to its board of directors as an independent director.

Syndax Names Steven M. Fruchtman, M.D., Chief Medical Officer

10/11/2013 04:11 pm

(Yahoo! Finance) Oct 11, 2013 - Syndax Pharmaceuticals Inc. today announced the appointment of Steven M. Fruchtman, M.D., a hematologist/oncologist with extensive experience in early and late-stage drug development with biopharmaceutical companies and in clinical practice, as chief medical officer.

Syndax Names Steven M. Fruchtman, M.D., Chief Medical Officer

10/11/2013 11:01 am

(Yahoo! Finance) Oct 11, 2013 - Syndax Pharmaceuticals Inc. today announced the appointment of Steven M. Fruchtman, M.D., a hematologist/oncologist with extensive experience in early and late-stage drug development with biopharmaceutical companies and in clinical practice, as chief medical officer.

Syndax's Entinostat Receives Breakthrough Therapy Designation from FDA for Treatment of Advanced Breast Cancer

9/11/2013 02:52 pm

(MarketWatch) Sep 11, 2013 - Syndax Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated entinostat as a Breakthrough Therapy for the treatment of locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer when added to exemestane in postmenopausal women whose disease has progressed following non-steroidal aromatase inhibitor therapy.

Syndax's Entinostat Receives Breakthrough Therapy Designation from FDA for Treatment of Advanced Breast Cancer

9/11/2013 09:05 am

(MarketWatch) Sep 11, 2013 - Syndax Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated entinostat as a Breakthrough Therapy for the treatment of locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer when added to exemestane in postmenopausal women whose disease has progressed following non-steroidal aromatase inhibitor therapy.

Syndax Pockets $26.6M For Final Stage Push With Cancer Drug

8/27/2013 04:29 pm

(Xconomy Boston) Aug 27, 2013 - Syndax Pharmaceuticals has spent eight years trying to show it can make existing cancer drugs work better by switching off certain enzymes implicated in tumor mutation.

Syndax Pockets $26.6M For Final Stage Push With Cancer Drug

8/27/2013 11:02 am

(Xconomy Boston) Aug 27, 2013 - Syndax Pharmaceuticals has spent eight years trying to show it can make existing cancer drugs work better by switching off certain enzymes implicated in tumor mutation.

AACR Opposes Bill to Exempt Cigars From FDA Regulation

5/2/2013 12:01 pm

(AACR) May 1, 2013 - The American Association for Cancer Research (AACR) formally issued letters to all members of the House of Representatives and the Senate urging them to oppose recently introduced legislation that would exempt many cigars from regulation.

Hopes Fade for AstraZeneca and Rigel's Arthritis Pill

12/13/2012 12:00 pm

(Reuters) Dec 13, 2012 - An experimental rheumatoid arthritis drug from AstraZeneca proved inferior to Abbott Laboratories' Humira in a clinical study, knocking hopes for one of the few late-stage products in the company's pipeline.

President Clinton Joins Breast Cancer Deadline 2020 as Honorary Chair of NBCC's Global Campaign

11/13/2012 11:03 am

(Huffington Post/The Blog) Nov 13, 2012 - Not long after we launched the National Breast Cancer Coalition, it was time to elect a new president for the country.

UC Davis Scientists Identify New Target for Lung Cancer Treatment

11/2/2012 10:02 am

(UC Davis Health System) Nov 1, 2012 - A team of UC Davis investigators has discovered a protein on the surface of lung cancer cells that could prove to be an important new target for anti-cancer therapy.

Metastatic Breast Cancer: Bevacizumab Slows Progression, But Has No Impact on Survival

7/11/2012 11:05 am

(Wiley) July 10, 2012 - The cancer drug bevacizumab (Avastin®) offers only a modest benefit in delaying disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane researchers.

Lung Cancer Study Showed Encouraging Results For ALIMTA-based Regimens And Full-dose Radiation

6/4/2012 05:05 pm

(Marketwatch) June 4, 2012 - Eli Lilly and Company announced results of a Phase II trial evaluating ALIMTA® (pemetrexed for injection) in combination with a platinum chemotherapy and radiation for patients with locally advanced non-small cell lung cancer (NSCLC).

Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO

5/29/2012 05:01 pm

(Boston Business Journal) May 29, 2012 - Syndax Pharmaceuticals, Inc., a late-stage oncology company, announced today that updated results from ENCORE 301, a randomized, placebo-controlled phase 2 study of exemestane with and without entinostat in estrogen receptor positive metastatic breast cancer demonstrated improvement in overall survival for patients treated with exemestane plus entinostat.

Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO

5/29/2012 12:00 pm

(Boston Business Journal) May 29, 2012 - Syndax Pharmaceuticals, Inc., a late-stage oncology company, announced today that updated results from ENCORE 301, a randomized, placebo-controlled phase 2 study of exemestane with and without entinostat in estrogen receptor positive metastatic breast cancer demonstrated improvement in overall survival for patients treated with exemestane plus entinostat.

Syndax Pharmaceuticals Appoints Arlene Morris as CEO

4/18/2012 06:08 pm

(Yahoo! Finance) Apr 18, 2012 - Syndax Pharmaceuticals, Inc., an oncology company moving into phase 3 having completed randomized, placebo controlled phase 2 studies, announced the appointment of Arlene M. Morris as chief executive officer. Joanna Horobin, MD will serve as president.

Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer

4/9/2012 05:12 pm

(Yahoo! Finance) Apr 9, 2012 - Investigators at The University of Texas MD Anderson Cancer Center Department of Breast Medical Oncology have initiated a phase 1/2 study combining Syndax's lead product entinostat with lapatinib ditosylate (Tykerb) in patients with locally recurrent or distant relapsed metastatic breast cancer previously treated with trastuzumab (Herceptin®).

Syndax Pharmaceuticals Signs Agreement with Ventana Medical Systems, Inc. to Develop Companion Diagnostic Test For Entinostat

1/5/2012 06:45 pm

(Reuters) Jan 5, 2012 - Syndax Pharmaceuticals, Inc. and Ventana Medical Systems, Inc. announced that the companies have entered into an agreement to develop a companion diagnostic assay to select patients with non-small cell lung cancer (NSCLC) for treatment with erlotinib and Syndax's proprietary lead molecule entinostat.

Syndax Pharmaceuticals Signs Agreement with Ventana Medical Systems, Inc. to Develop Companion Diagnostic Test For Entinostat

1/5/2012 06:45 pm

(Reuters) Jan 5, 2012 - Syndax Pharmaceuticals, Inc. and Ventana Medical Systems, Inc. announced that the companies have entered into an agreement to develop a companion diagnostic assay to select patients with non-small cell lung cancer (NSCLC) for treatment with erlotinib and Syndax's proprietary lead molecule entinostat.

Survival Benefit With Syndax Pharmaceuticals' Entinostat Maintained in Women With Advanced Breast Cancer

12/8/2011 08:41 pm

(TheStreet) Dec 7, 2011 - Syndax Pharmaceuticals, Inc. announced today that, with a 23-month patient follow up of ENCORE 301, a multicenter, randomized, double-blind, placebo-controlled, phase 2 study of exemestane with and without entinostat in 130 patients with locally recurrent or metastatic estrogen receptor-positive breast cancer, the median overall survival of exemestane plus entinostat patients reached 26.9 months versus 19.8 months for exemestane plus placebo.

Lead Syndax Drug Shows Survival Benefits in Breast Cancer Trial

9/7/2011 04:59 pm

(Xconomy Boston) Sept 6, 2011 - Just two months after reporting positive data from a clinical trial of its lead drug candidate in lung cancer, Waltham, MA-based Syndax said today that the same drug performed well in a Phase 2 breast cancer trial.

Results of Syndax Pharmaceutical's ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the ASCO Breast Cancer Symposium 2011

8/24/2011 04:22 pm

(Yahoo! Finance) Aug 24, 2011 - Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced today that safety and efficacy data from ENCORE 301 will be presented in an oral session at the ASCO Breast Cancer Symposium 2011 on Saturday, September 10 in San Francisco, CA.

Syndax Moves Closer to Pivotal Trials of Selective Lung Cancer Treatment

7/5/2011 05:28 pm

(Xconomy Boston) July 5, 2011 - Executives from Syndax Pharmaceuticals are spending their post-holiday week in Amsterdam, where they’ll be presenting three sets of data on the company’s lung cancer drug at the International Association for the Study of Lung Cancer conference.

FDA Approves New Drug to Treat Lupus

3/10/2011 01:00 pm

(Washington Post) Mar 9, 2011 - The Food and Drug Administration approved the first treatment designed for lupus in half a century Wednesday, a decision that stands to generate billions of dollars over several years for Human Genome Sciences of Rockville and its development partner, GlaxoSmithKline.